133 related articles for article (PubMed ID: 35247918)
1. Inhibition of Oxidized Nucleotide Sanitation By TH1579 and Conventional Chemotherapy Cooperatively Enhance Oxidative DNA Damage and Survival in AML.
Centio A; Estruch M; Reckzeh K; Sanjiv K; Vittori C; Engelhard S; Warpman Berglund U; Helleday T; Theilgaard-Mönch K
Mol Cancer Ther; 2022 May; 21(5):703-714. PubMed ID: 35247918
[TBL] [Abstract][Full Text] [Related]
2. MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia.
Sanjiv K; Calderón-Montaño JM; Pham TM; Erkers T; Tsuber V; Almlöf I; Höglund A; Heshmati Y; Seashore-Ludlow B; Nagesh Danda A; Gad H; Wiita E; Göktürk C; Rasti A; Friedrich S; Centio A; Estruch M; Våtsveen TK; Struyf N; Visnes T; Scobie M; Koolmeister T; Henriksson M; Wallner O; Sandvall T; Lehmann S; Theilgaard-Mönch K; Garnett MJ; Östling P; Walfridsson J; Helleday T; Warpman Berglund U
Cancer Res; 2021 Nov; 81(22):5733-5744. PubMed ID: 34593524
[TBL] [Abstract][Full Text] [Related]
3. TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model.
Moukengue B; Brown HK; Charrier C; Battaglia S; Baud'huin M; Quillard T; Pham TM; Pateras IS; Gorgoulis VG; Helleday T; Heymann D; Berglund UW; Ory B; Lamoureux F
EBioMedicine; 2020 Mar; 53():102704. PubMed ID: 32151797
[TBL] [Abstract][Full Text] [Related]
4. Targeted inhibition of cooperative mutation- and therapy-induced AKT activation in AML effectively enhances response to chemotherapy.
Estruch M; Reckzeh K; Vittori C; Centio A; Ali M; Engelhard S; Zhao L; Won KJ; Liu P; Porse BT; Theilgaard-Mönch K
Leukemia; 2021 Jul; 35(7):2030-2042. PubMed ID: 33299144
[TBL] [Abstract][Full Text] [Related]
5. Adaptation to Chronic-Cycling Hypoxia Renders Cancer Cells Resistant to MTH1-Inhibitor Treatment Which Can Be Counteracted by Glutathione Depletion.
Hansel C; Hlouschek J; Xiang K; Melnikova M; Thomale J; Helleday T; Jendrossek V; Matschke J
Cells; 2021 Nov; 10(11):. PubMed ID: 34831264
[TBL] [Abstract][Full Text] [Related]
6. Mitocurcumin utilizes oxidative stress to upregulate JNK/p38 signaling and overcomes Cytarabine resistance in acute myeloid leukemia.
Gaur T; Ali A; Sharma D; Gupta SK; Gota V; Bagal B; Platzbeckar U; Mishra R; Dutt A; Khattry N; Mills K; Hassan MI; Sandur S; Hasan SK
Cell Signal; 2024 Feb; 114():111004. PubMed ID: 38048856
[TBL] [Abstract][Full Text] [Related]
7. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.
Doshi KA; Trotta R; Natarajan K; Rassool FV; Tron AE; Huszar D; Perrotti D; Baer MR
Oncotarget; 2016 Jul; 7(30):48280-48295. PubMed ID: 27374090
[TBL] [Abstract][Full Text] [Related]
8. Overexpressed c-Myc Sensitizes Cells to TH1579, a Mitotic Arrest and Oxidative DNA Damage Inducer.
Henriksson S; Calderón-Montaño JM; Solvie D; Warpman Berglund U; Helleday T
Biomolecules; 2022 Nov; 12(12):. PubMed ID: 36551206
[TBL] [Abstract][Full Text] [Related]
9. MTH1 as a target to alleviate T cell driven diseases by selective suppression of activated T cells.
Karsten S; Fiskesund R; Zhang XM; Marttila P; Sanjiv K; Pham T; Rasti A; Bräutigam L; Almlöf I; Marcusson-Ståhl M; Sandman C; Platzack B; Harris RA; Kalderén C; Cederbrant K; Helleday T; Warpman Berglund U
Cell Death Differ; 2022 Jan; 29(1):246-261. PubMed ID: 34453118
[TBL] [Abstract][Full Text] [Related]
10. Antitumour activity of TH1579, a novel MTH1 inhibitor, against castration-resistant prostate cancer.
Hu M; Ning J; Mao L; Yu Y; Wu Y
Oncol Lett; 2021 Jan; 21(1):62. PubMed ID: 33281973
[TBL] [Abstract][Full Text] [Related]
11. Validation and development of MTH1 inhibitors for treatment of cancer.
Warpman Berglund U; Sanjiv K; Gad H; Kalderén C; Koolmeister T; Pham T; Gokturk C; Jafari R; Maddalo G; Seashore-Ludlow B; Chernobrovkin A; Manoilov A; Pateras IS; Rasti A; Jemth AS; Almlöf I; Loseva O; Visnes T; Einarsdottir BO; Gaugaz FZ; Saleh A; Platzack B; Wallner OA; Vallin KS; Henriksson M; Wakchaure P; Borhade S; Herr P; Kallberg Y; Baranczewski P; Homan EJ; Wiita E; Nagpal V; Meijer T; Schipper N; Rudd SG; Bräutigam L; Lindqvist A; Filppula A; Lee TC; Artursson P; Nilsson JA; Gorgoulis VG; Lehtiö J; Zubarev RA; Scobie M; Helleday T
Ann Oncol; 2016 Dec; 27(12):2275-2283. PubMed ID: 27827301
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of MTH1 inhibition-induced DNA strand breaks: The slippery slope from the oxidized nucleotide pool to genotoxic damage.
Rai P; Sobol RW
DNA Repair (Amst); 2019 May; 77():18-26. PubMed ID: 30852368
[TBL] [Abstract][Full Text] [Related]
13. A Double-Edged Sword: The Anti-Cancer Effects of Emodin by Inhibiting the Redox-Protective Protein MTH1 and Augmenting ROS in NSCLC.
Wahi D; Soni D; Grover A
J Cancer; 2021; 12(3):652-681. PubMed ID: 33403025
[No Abstract] [Full Text] [Related]
14. FLT3-ITD cooperates with Rac1 to modulate the sensitivity of leukemic cells to chemotherapeutic agents via regulation of DNA repair pathways.
Wu M; Li L; Hamaker M; Small D; Duffield AS
Haematologica; 2019 Dec; 104(12):2418-2428. PubMed ID: 30975911
[TBL] [Abstract][Full Text] [Related]
15. MTH1 deficiency selectively increases non-cytotoxic oxidative DNA damage in lung cancer cells: more bad news than good?
Abbas HHK; Alhamoudi KMH; Evans MD; Jones GDD; Foster SS
BMC Cancer; 2018 Apr; 18(1):423. PubMed ID: 29661172
[TBL] [Abstract][Full Text] [Related]
16. SIRT3 deacetylase activity confers chemoresistance in AML via regulation of mitochondrial oxidative phosphorylation.
Ma J; Liu B; Yu D; Zuo Y; Cai R; Yang J; Cheng J
Br J Haematol; 2019 Oct; 187(1):49-64. PubMed ID: 31236919
[TBL] [Abstract][Full Text] [Related]
17. Mitotic MTH1 Inhibitors in Treatment of Cancer.
Helleday T
Cancer Treat Res; 2023; 186():223-237. PubMed ID: 37978139
[TBL] [Abstract][Full Text] [Related]
18. Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia.
Hosseini M; Rezvani HR; Aroua N; Bosc C; Farge T; Saland E; Guyonnet-Dupérat V; Zaghdoudi S; Jarrou L; Larrue C; Sabatier M; Mouchel PL; Gotanègre M; Piechaczyk M; Bossis G; Récher C; Sarry JE
Cancer Res; 2019 Oct; 79(20):5191-5203. PubMed ID: 31358527
[TBL] [Abstract][Full Text] [Related]
19. Blockade of JAK2/STAT3 intensifies the anti-tumor activity of arsenic trioxide in acute myeloid leukemia cells: Novel synergistic mechanism via the mediation of reactive oxygen species.
Mesbahi Y; Zekri A; Ghaffari SH; Tabatabaie PS; Ahmadian S; Ghavamzadeh A
Eur J Pharmacol; 2018 Sep; 834():65-76. PubMed ID: 30012499
[TBL] [Abstract][Full Text] [Related]
20. Impact of an Additional Chromosome on the Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Acute Myeloid Leukemia in Adults.
Min GJ; Kim HJ; Yoon JH; Kwak DH; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1621-1628. PubMed ID: 29698793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
